Greenbrook TMS Announces Dates for Its Third Quarter 2022 Financial Results

Rhea-AI Summary

Greenbrook TMS Inc. (NASDAQ: GBNH) will announce its 2022 third quarter operational and financial results after market hours on November 8, 2022. A conference call is scheduled for November 9, 2022, at 10:00 a.m. ET, hosted by CEO Bill Leonard and CFO Erns Loubser, to discuss the results. Greenbrook operates 191 treatment centers in the U.S., specializing in FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder. The company has administered over 900,000 TMS treatments to more than 25,000 patients.

Positive

• Leading provider of FDA-cleared TMS therapy with 191 treatment centers.
• Administered over 900,000 TMS treatments to more than 25,000 patients, indicating strong operational performance.

Negative

• None.

TORONTO--(BUSINESS WIRE)-- Greenbrook TMS Inc. (TSX: GTMS, NASDAQ: GBNH) (“Greenbrook” or the “Company”), will release its 2022 third quarter operational and financial results after market hours on November 8, 2022.

THIRD QUARTER 2022 CONFERENCE CALL DETAILS:

Bill Leonard, President and Chief Executive Officer, and Erns Loubser, Chief Financial Officer, will host a conference call at 10:00 a.m. (Eastern Time) on November 9, 2022 to discuss the financial results for the quarter.

Dial in Numbers:

Toll Free North America: 1 (888) 886-7786
Toronto: (416) 764-8658

Webcast:

For more information or to listen to the call via webcast, please visit:
www.greenbrooktms.com/investors/events.htm

For those that plan on accessing the conference call or webcast, please allow ample time prior to the call time.

Conference Call Replay:

Following the live call, a replay will be available on the Investor Relations section of the Company’s website, www.greenbrooktms.com/investors/events.htm

About Greenbrook TMS Inc.

Operating through 191 Company-operated treatment centers, Greenbrook is a leading provider of Transcranial Magnetic Stimulation (“TMS”) therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, in the United States. TMS therapy provides local electromagnetic stimulation to specific brain regions known to be directly associated with mood regulation. Greenbrook has provided more than 900,000 TMS treatments to over 25,000 patients struggling with depression.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026005796/en/

For further information:

Glen Akselrod

Investor Relations

Greenbrook TMS Inc.

Contact Information:

investorrelations@greenbrooktms.com

1-855-797-4867

Source: Greenbrook TMS Inc.

FAQ

When will Greenbrook TMS Inc. release its Q3 2022 results?

Greenbrook TMS Inc. will release its Q3 2022 results after market hours on November 8, 2022.

What time is the Q3 2022 conference call for Greenbrook TMS Inc.?

The Q3 2022 conference call for Greenbrook TMS Inc. will be held at 10:00 a.m. ET on November 9, 2022.

Who will host the conference call for Greenbrook's Q3 2022 results?

Bill Leonard, President and CEO, and Erns Loubser, CFO, will host the conference call.

What is Greenbrook TMS's primary business focus?

Greenbrook TMS specializes in providing FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy for Major Depressive Disorder and other mental health disorders.